Our formulations are third-party tested for purity and potency, ensuring that what is on the label is exactly what is in the product
Currently, there are seven different approved GLP-1RAs on the market: liraglutide once daily, semaglutide once weekly, exenatide extended-release (ER) once weekly, dulaglutide once weekly, oral semaglutide once daily, exenatide twice daily, and lixisenatide once daily
George, Utah, or fully online by telehealth anywhere in Utah
Tesamorelin vs Sermorelin: Choosing the Right Peptide for Your Research Choose Tesamorelin When: The primary research endpoint is visceral adipose tissue (VAT) reduction Rapid, measurable IGF-1 elevation is needed within a short protocol window Studying metabolic syndrome, abdominal obesity, or lipodystrophy models Extended protocol stability is required (tesamorelin resists enzymatic degradation better) Research budget supports a higher-cost compound for a shorter, intensive protocol Choose Sermorelin When: The focus is long-term endocrine system support and hormonal homeostasis Sleep architecture and recovery pathways are the primary study variables Anti-aging, collagen synthesis, or longevity markers are being investigated A physiological, pulsatile GH release pattern is required to preserve feedback loops Cost efficiency over a long-duration protocol is a consideration The comparison extends beyond just these two peptides
Van der Ploeg, L
Understanding what BPC-157 is and how it functions helps contextualize its potential relevance to lupus
.png)
